Activ-3

In the race to get COVID-19 treatment options to market, Eli Lilly is the latest to suffer a setback. What Happened: The New York Times reports Eli Lilly and Co (NYSE: LLY) paused its Phase 3 clinical trial for the ACTIV-3 antibody treatment. The pause comes as there is a...